Prevalence, Immunotherapy Use in Anorectal Mucosal Melanoma Found to Be Increasing
A retrospective study identified incidence of and treatment trends for anorectal mucosal melanoma tumors.
Skin Cancer News
SKIN CANCER ADVISOR
Skin Cancer News
Keytruda Approved for the Adjuvant Treatment of Patients With Stage III Melanoma
Merck announced that the Food and Drug Administration (FDA) has approved Keytruda(pembrolizumab) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. This marks the first approval for Keytruda in the adjuvant setting and the fourth approval for its use in skin cancers. The approval was supported by data from the phase 3,…
Imatinib Found to Be Effective in Unresectable Dermatofibrosarcoma Protuberans
Eight in 10 patients with DFSP saw a clinical benefit from treatment with imatinib.
Specific T Cells Play Key Role in Melanoma-Immune Equilibrium
Tissue-resident memory CD8+ T cells helped suppress melanoma in an animal study.
Nomogram Predicts Melanoma Recurrence Risk After Negative Sentinel Node Biopsy
Current treatment guidelines do not adequately cover what kind of surveillance and treatment should apply to patients with melanoma after a negative sentinel node biopsy.
Keytruda Gains Merkel Cell Carcinoma Indication
The Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
BRAF Splice Variants May Mediate Resistance to RAF Inhibitors in Patients with Melanoma
The discovery could provide opportunities to target resistance driven by aberrantly spliced forms of BRAF V600E.
Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
Pembrolizumab plus dabrafenib and trametinib showed a nonsignificant improvement in PFS, but also higher rates of grade 3 to grade 5 TRAEs in advanced melanoma.
First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma
First-line nivolumab with or without ipilimumab continues to show durable survival benefits in advanced, unresectable melanoma.
Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
T-VEC elicited substantially higher ORR in a real-world population compared with the rate that was seen in the drug maker’s phase 3 trial.
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear
Treatment with ipilimumab plus nivolumab in the neoadjuvant setting resulted in high patient response rates — but it was linked to high toxicity, as well.
Neoadjuvant Combination Checkpoint Inhibition May Be Feasible for Stage III Melanoma
Future studies on checkpoint inhibition in melanoma must evaluate ways of reducing toxicity.
Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.
Predictors of Response to Checkpoint Inhibitors in Melanoma Revealed
A computational tool appears to accurately tease out the portion of patients who might respond to checkpoint inhibitors from those who are likely to be resistant.
Limited Local Lymph Node Excision Plus Radiotherapy May Be Effective in Melanoma
Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.
Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma
Previous studies have demonstrated that the vascular endothelial growth factor inhibitor bevacizumab is active in melanoma, and may be effective in the maintenance setting.
Frequency of Tanning, Risk for Melanoma Higher in Gym Tanners
The use of tanning beds and/or booths and their availability in gyms may increase the frequency of indoor tanning for physically active adults, a combination that further exacerbates their risk for melanoma.
Do Sunless Tanners Have Fewer Skin Cancer Risk Behaviors?
People who elect to undergo sunless tanning tend to continue behaviors that could increase their risk of skin cancer.
Skin Cancer Education May Improve Sun Protection Practices Among Organ Transplant Recipients
The use of multiple sun protection measures was defined as the use of 2 or more of these measures more than 50% of the time when the individual was outdoors.
Want to read more?
Please login or register first to view this content.
